^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JS108
i
Other names: JS108, DAC-002, recombinant humanized anti-Trop2 mAb-Tub196 conjugate, JS-108, JS 108, DAC 002, DAC002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hangzhou DAC Biotech, Shanghai Junshi Biosci
Drug class:
Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
Related drugs:
over1year
A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=25, Terminated, Shanghai Junshi Bioscience Co., Ltd. | N=153 --> 25 | Trial completion date: Nov 2023 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jun 2023; Sponsor has adjusted study development plan and terminated this clinical study.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
JS108
Share via
